Scientific Research and Essays

  • Abbreviation: Sci. Res. Essays
  • Language: English
  • ISSN: 1992-2248
  • DOI: 10.5897/SRE
  • Start Year: 2006
  • Published Articles: 2748

Full Length Research Paper

Effects of an additional pharmaceutical care intervention versus usual care on clinical outcomes of Type 2 diabetes patients in Nigeria: A comparative study

Maxwell Ogochukwu Adibe
  • Maxwell Ogochukwu Adibe
  • Pharmaceutical Outcomes Research Team, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria, P. O. Box 410001 Nsukka, Enugu State, Nigeria.
  • Google Scholar
Udeogaranya Pactrick Obinna
  • Udeogaranya Pactrick Obinna
  • Pharmaceutical Outcomes Research Team, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria, P. O. Box 410001 Nsukka, Enugu State, Nigeria.
  • Google Scholar
Igboeli Nneka Uchenna
  • Igboeli Nneka Uchenna
  • Pharmaceutical Outcomes Research Team, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria, P. O. Box 410001 Nsukka, Enugu State, Nigeria.
  • Google Scholar
Ubaka Chukwuemeka Michael
  • Ubaka Chukwuemeka Michael
  • Pharmaceutical Outcomes Research Team, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria, P. O. Box 410001 Nsukka, Enugu State, Nigeria.
  • Google Scholar
Cletus Nze Aguwa
  • Cletus Nze Aguwa
  • Pharmaceutical Outcomes Research Team, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria, P. O. Box 410001 Nsukka, Enugu State, Nigeria.
  • Google Scholar


  •  Received: 07 June 2013
  •  Accepted: 16 May 2014
  •  Published: 30 June 2014

References

ADA (2011), American Diabetes Association. Standards of medical care in diabetes [Position Statement]. Diabetes Care 34 (Suppl. 1): S11-S61.
Pubmed
 
Akanji A, Adetunji A (1990). The pattern of presentation of foot lesions in Nigerian diabetic patients. W. Afr. J. Med. 9:1-5.
Pubmed
 
Al-Mazroui N, Kamal M, Ghabash N, Yacout T, Kole P, McElnay J (2009). Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. Brit. J. Clin. Pharmacol. 67: 547-557.
Crossref
 
Campbell D, Stanley J (1963). Experimental and Quasi-Experimental Designs for Research. Chicago, Illinois: Rand McNally College Publishing Company.
 
Castro MS, Fuchs FD, Santos MC, Maximiliano P, Gus M, Moreira LB, Ferreira MB (2006). Pharmaceutical care program for patients with uncontrolled hypertension: Report of a double-bind clinical trial with ambulatory blood pressure. Am. J. Hypertens. 19:528-533.
Crossref
 
Clifford R, Batty K, Davis T, Davis W, Stein G, Stewart G, Plumridge RJ (2002). A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int. J. Pharm. Pract. 10:85- 89.
Crossref
 
Clifford R, Batty K, Davis T, Davis W (2005). Effect of a Pharmaceutical Care Program on Vascular Risk Factors in Type 2 Diabetes (The Fremantle Diabetes Study). Diabetes Care 28:771-776.
Crossref
 
Coast-Senior E, Kroner B, Kelley C, Trili L (1998). Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann. Pharmacother. 32:636-641.
Crossref
 
Cook T, Campbell D (1979). Quasi-experimentation. Design and Analysis Issues for Field Studies. Chicago, Illinois: Rand McNally College Publishing Company.
 
Cranor C, Christensen D (2003). The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J. Am. Pharm. Assoc. 43:149-159.
Crossref
 
Davis TM, Clifford RM, Davis WA, Batty KT (2005). The role of pharmaceutical care in diabetes management. Br. J. Diabetes Vasc. Dis. 5(6):352-356.
Crossref
 
DCCT (1993). The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 329:977-986.
Crossref
 
Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O (2000). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl. J. Med. 348:383393.
 
Garrett D, Bluml B (2005). Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes. J. Am. Pharm. Assoc. 45:130-137.
Crossref
 
Hawkins D, Bradberry JC, Cziraky MJ, Talbert RL, Bartles DW, Cerveny JD (2002). National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: Toward better patient outcomes and new roles for pharmacists. Pharmacotherapy 22(4):436-444.
Crossref
 
Hepler C, Strand L (1990). Opportunities and responsibilities in pharmaceutical care. Am. J. Hosp. Pharm. 47:533-543.
Pubmed
 
International diabetes federation: Diabetes atlas.
 
Jaber L, Halapy H, Fenret M, Tummalapalli S, Diwakaran H (1996). Evaluation of a pharmaceutical care model on diabetes management. Ann. Pharmacother. 30:238-243.
Pubmed
 
Keil P, McCord A (2005). Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann. Pharmacother. 39: 1828-1832.
Crossref
 
Kennie N, Schuster B, Einarson T (1998). Critical analysis of the pharmaceutical care research literature. Ann Pharmacother. 32:17-26.
Pubmed
 
Khan CR, Weir GC, King GL, Moses AC (2004). Joselin's Diabetes Mellitus. 14th ed. Philadelphia: Lippincott Williams & Wilkins.
 
Krass I, Taylor S, Carlene S, Armour C (2005). Impact on medication use and adherence of Australian Pharmacist's Diabetes Care Services. J. Am. Pharm. Assoc. 45: 33-40.
Crossref
 
Lee J, Grace K, Taylor A (2006). Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. J. Am. Med. Assoc. 296: 2563-2571.
Crossref
 
Machado M, Bajcar J, Guzzo G, Einarson T (2007). Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann. Pharmacother. 41: 1770-1781.
Crossref
 
Mads-Haahr Random Sequence Generator (1998-2011).
 
Majumdar SR, Guirguis LM, Toth EL, Lewanczuk RZ, Lee TK, Johnson JA (2003). Controlled trial of a multifaceted intervention for improving quality of care for rural patients with type 2 diabetes. Diabetes Care 26: 3061-3066.
Crossref
 
Mazzolini T, Irons B, Schell E, Seifert C (2005). Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical clinics Centers. J. Manage Care Pharm. 11: 763-771.
Pubmed
 
Nyenwe E, Odia O, Ihekwala A, Ojule A, Babatunde S (2003). Type 2 diabetes in adult Nigerians: A study of its prevalent and risk factors in Port Harcourt, Nigeria. Diab. Res. Clin. Pr. 62:177-185.
Crossref
 
Odili VU, Ugboka LU, Oparah AC (2010). Quality of life people with diabetes in Benin City as measured with WHOQoL-BREF. Internet J. Law Healthc. Ethics 6(2).
 
Sack D, Bruns D, Goldstein D, Maclaren N, McDonald J, Parrott M (2002). Guidelines and recommendations forlaboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 48:436-472.
 
Sadur C, Moline N, Costa M. Michalik D, Mendlowitz D, Roller S, Watson R, Swain BE, Selby JV, Javorski WC (1999). Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care 22:2011-2017.
Crossref
 
Shaw J, Sicree R, Zimmet P (2010). Global estimates of the prevalence of diabetes. Diab. Res Clin. Pr. 87:4-14.
Crossref
 
Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C, Hadden D, Turner RC, Holman RR (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Brit. Med. J. 321:405-412.
Crossref
 
UKPDS (1998). UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853.
Crossref
 
Viberti G (2003). The need for tighter control of cardiovascular risk factors in diabetic patients. J. Hypertens. 21(Suppl. 1):S3-S6.